News release

Strong life sciences demand fuels $82M sale of Fremont Labs

JLL Capital Markets led the sales efforts for the Class A life sciences asset in the Bay area’s Central I-880 corridor 

August 01, 2022

Kristen Murphy

Capital Markets, Hotels & Hospitality and Value & Risk Advisory PR
+1 617 848 1572

SAN FRANCISCO – August 1, 2022 – JLL Capital Markets announced today that it has closed the $82 million sale of Fremont Labs, a recently renovated, Class A life sciences property totaling 89,000 square feet in Fremont, California.

JLL represented the seller, a joint venture between Jadian Capital and Graymark Capital, and procured the buyer, Diversified Healthcare Trust (DHC), which is managed by The RMR Group. This acquisition marks DHC’s fourth life science acquisition in the San Francisco Bay area and expands the company’s total Bay Area holdings to six.

Fremont Labs is positioned on a 4.7-acre site at 47071 Bayside Pkwy within the Central I-880 corridor of San Francisco. Given San Francisco’s rank as the second largest life sciences market in the U.S., the property is surrounded by major life sciences users, is within close proximity to a highly educated labor pool and is close to the world-class research institutions at San Jose State University, Stanford University and Santa Clara University.

Recently renovated in 2022, Fremont Labs is fully leased as the headquarters location for Alamar BioSciences, a pre-clinical stage proteomics (disease detection) company. The two-story building features collaborative open floorplans, premium lab space with airlocks, backup power, double loading docks and 21’ ceiling heights, all ideal attributes for life sciences tenants. In addition, tenants have access to an on-site fitness center and cafeteria. Overall, Fremont Labs offers 56% office, 30% lab and 14% manufacturing and warehouse space.

The JLL Capital Markets team representing the seller was led by Managing Director Adam Lasoff, Senior Directors Dan Renz and Erik Hanson, Director Michael Manas, Senior Managing Director Will Connors, Vice President Cheri Pierce and Analyst Johnny VanDerVelden.

“Jadian and Graymark are the first investors in this market to successfully execute on a life science conversion and exit for core pricing,” Lasoff said. “This is in part due to the strength of the Bay Area life sciences and biotech market, which is one of the strongest in the country.

JLL Capital Markets is a full-service global provider of capital solutions for real estate investors and occupiers. The firm's in-depth local market and global investor knowledge delivers the best-in-class solutions for clients — whether investment sales advisory, debt placement, equity placement or a recapitalization. The firm has more than 3,700 Capital Markets specialists worldwide with offices in nearly 50 countries.

For more news, videos and research resources on JLL, please visit our newsroom.

About JLL

JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces and sustainable real estate solutions for our clients, our people and our communities. JLL is a Fortune 500 company with annual revenue of $19.4 billion, operations in over 80 countries and a global workforce of more than 100,000 as of March 31, 2022. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit

About Jadian Capital

Founded in 2017, Jadian is a New York and Stamford, Connecticut based investment firm targeting opportunities throughout the capital structures of real estate, related assets and asset-intensive businesses.  With a value-oriented, opportunistic approach, Jadian’s core mission is to craft investments in undervalued, high-quality assets.  The firm’s strategy focuses primarily on non-core sectors with characteristics likely to lead to long-term fundamental outperformance.  Jadian actively manages a portfolio of investments across the capital structure and its principals have a history of successfully executing investments across cycles, with diverse expertise in platform creation, distress, equity and credit.

About Graymark Capital

Graymark Capital is an industry-leading commercial real estate firm, headquartered in San Francisco, California. The firm invests in institutional quality life science, office, R & D and industrial properties in the Western U.S. that appeal to today's modern tenants. Since 2012, Graymark Capital has purchased 28 life science, office, R&D and industrial properties comprising over 3.5 million square feet and over $1.7 billion of value.